Subscribe to RSS
DOI: 10.1055/s-0030-1270522
© Georg Thieme Verlag KG Stuttgart · New York
Increased Gallium-68 DOTATOC Uptake in Normal Thyroid Glands
Publication History
received 21.11.2010
accepted 14.12.2010
Publication Date:
24 January 2011 (online)

Abstract
Increased Ga-68 DOTATOC uptake for normal and goitrous and/or nodular thyroids has previously been reported for a small number of patients. The aim of this study was to reevaluate these preliminary findings with larger patient numbers and to determine possible variables, which might influence the quantification of Ga-68 DOTATOC uptake in normal and pathologic thyroid tissues. Ga-68 DOTATOC PET scans of 165 patients classified for various thyroid pathologies were analyzed by the so-called region of interest technique for Ga-68 DOTATOC uptake and the patient's history, thyroid ultrasound, TSH, and anti-TPO antibodies. Thyroid glands without any pathology showed a clearly detectable uptake of Ga-68 DOTATOC with a large variability and significantly higher target to background ratios for men as compared to women. In 8 cases of normal thyroids with an increased uptake, follow-up examinations after 6–14 months did not show any thyroid pathology. An increased DOTATOC uptake (target to background ratio >3.4) was found in hot nodules, disseminated thyroid autonomy, and in most cases (5 of 8) of active Hashimoto's disease. In Ga-68 DOTATOC PET, normal thyroid glands show a clearly detectable radiotracer uptake with a large variability and significantly higher target to background ratios in male patients. All patients with thyroid autonomy and most patients with active Hashimoto's disease have an increased thyroid DOTATOC uptake.
Key words
Ga-68 DOTATOC - PET - thyroid gland - SSTR - relative quantification - normal thyroid - thyroid nodules
References
- 1
Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A.
Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone
secretion in human somatotroph tumors.
J Clin Endocrinol Metab.
2001;
86
2976-2981
MissingFormLabel
- 2
Krantic S, Goddard I, Saveanu A, Giannetti N, Fombonne J, Cardoso A, Jaquet P, Enjalbert A.
Novel modalities of somatostatin actions.
Eur J Endocrinol.
2004;
151
643-655
MissingFormLabel
- 3
Becker W, Schrell U, Buchfelder M, Hensen J, Wendler J, Gramatzki M, Wolf F.
Somatostatin receptor expression in the thyroid demonstrated with 111In-octreotide
scintigraphy.
Nuklearmedizin.
1995;
34
100-103
MissingFormLabel
- 4
Rambaldi PF, Cuccurullo V, Briganti V, Mansi L.
The present and future role of 111In Pentetreotide in the PET era.
Q J Nucl Med Mol Imaging.
2005;
49
225-235
MissingFormLabel
- 5
Hofland LJ, Lamberts SW, van Hagen PM, Reubi JC, Schaeffer J, Waaijers M, van Koetsveld PM, Srinivasan A, Krenning EP, Breeman WA.
Crucial role for somatostatin receptor subtype 2 in determining the uptake of 111In-DTPA-DPhe1
octreotide in somatostatin receptor-positive organs.
J Nucl Med.
2003;
44
1315-1321
MissingFormLabel
- 6
Maecke HR, Hofmann M, Haberkorn U.
(68)Ga-labeled peptides in tumor imaging.
J Nucl Med.
2005;
46
172S-178S
MissingFormLabel
- 7
Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A.
Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic
neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
Eur J Nucl Med Mol Imaging.
2006;
33
1115-1122
MissingFormLabel
- 8
Patel YC, Srikant CB.
Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors
(hsstr 1–5).
Endocrinology.
1994;
135
2814-2817
MissingFormLabel
- 9
Bruns C, Raulf F, Hoyer D, Schloos J, Lübbert H, Weckbecker G.
Binding properties of somatostatin receptor subtypes.
Metabolism.
1996;
45
17-20
MissingFormLabel
- 10
Ain KB, Taylor KD.
Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in
vitro.
J Clin Endocrinol Metab.
1994;
78
1097-1102
MissingFormLabel
- 11
Medina DL, Toro M-J, Santisteban P.
Somatostatin interferes with thyrotropin-induced G1-S transition mediated by cAMP-dependent
protein kinase and phosphatidylinositol 3-kinase. Involvement of RhoA and cyclin E
x cyclin-dependent kinase 2 complexes.
J Biol Chem.
2000;
275
15549-15556
MissingFormLabel
- 12
Lattuada D, Casnici C, Crotta K, Mastrotto C, Franco P, Schmid HA, Marelli O.
Inhibitory effect of pasireotide and octreotide on lymphocyte activation.
J Neuroimmunol.
2007;
182
153-159
MissingFormLabel
- 13
Medina DL, Velasco JA, Santisteban P.
Somatostatin is expressed in FRTL-5 thyroid cells and prevents thyrotropin-mediated
down-regulation of the cyclin-dependent kinase inhibitor p27kip1.
Endocrinology.
1999;
140
87-95
MissingFormLabel
- 14
Lincke T, Singer J, Kluge R, Sabri O, Paschke R.
Relative quantification of In-111 Pentetreotide and Ga-68 DOTATOC uptake in the thyroid
gland and association with thyroid pathologies.
Thyroid.
2009;
19
381-389
MissingFormLabel
- 15
Yüksel M, Eziddin S, Wardelmann E, Biersack HJ.
111In-Pentetreotide uptake in a follicular adenoma of the thyroid gland: a pitfall
for 111In-Pentetreotide scintigraphy.
Rev Esp Med Nucl.
2006;
25
316-319
MissingFormLabel
- 16
Koriyama N, Nakazaki M, Hashiguchi H, Aso K, Ikeda Y, Kimura T, Eto H, Hirano H, Nakano S, Tei C.
Thyrotropin-producing pituitary adenoma associated with Graves’ disease.
Eur J Endocrinol.
2004;
151
587-594
MissingFormLabel
- 17
Krassas GE, Kahaly GJ.
The role of octreoscan in thyroid eye disease.
Eur J Endocrinol.
1999;
140
373-375
MissingFormLabel
- 18
Zatelli MC, degli Uberti EC.
Somatostatin receptors: from basic science to clinical approach – thyroid.
Dig Liver Dis.
2004;
36
86-92
MissingFormLabel
- 19
Krummenauer F.
Statistics in medical publications: Check lists for Authors.
Klin Monbl Augenheilkd.
2003;
220
362-365
MissingFormLabel
- 20
Druckenthaner M, Schwarzer C, Ensinger C, Gabriel M, Prommegger R, Riccabona G, Decristoforo C.
Evidence for Somatostatin receptor 2 in thyroid tissue.
Regul Pept.
2007;
138
32-39
MissingFormLabel
- 21
Kahaly G, Gorges R, Diaz M, Hommel G, Bockisch A.
Indium-111-pentetreotide in Graves’ disease.
J Nucl Med.
1998;
39
533-536
MissingFormLabel
- 22
Gorancini S, La Rosa S, De Palma D, Uccella S, Golonia F.
Uptake of In-111-pentetreotide by normally functioning nodular goiters.
Clin Nucl Med.
1997;
22
625-627
MissingFormLabel
Correspondence
R. Paschke
Medical Department III,
University of Leipzig
Liebigstraße 20
04103 Leipzig
Germany
Phone: +49/341/97 13201
Fax: +49/341/97 13209
Email: ralf.paschke@medizin.uni-leipzig.de